The effect of age and quality of life on doctors' decisions to anticoagulate patients with atrial fibrillation

被引:8
作者
Sudlow, M [1 ]
Thomson, R
Rodgers, H
Livingstone, S
Kenny, RA
机构
[1] Newcastle Univ, Sch Med, Dept Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[2] Newcastle Univ, Sch Med, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
关键词
age factors; anticoagulants; atrial fibrillation; cerebral embolism and thrombosis; cerebrovascular disorders; physicians practice patters; quality of life; warfarin;
D O I
10.1093/ageing/27.3.285
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Introduction: we report the results of a questionnaire survey into the effect of patients' age and of medico-social factors on hospital consultants' and general practitioners' reported use of warfarin anticoagulation to treat patients with non-valvular atrial fibrillation (NVAF). Methods: half of the general practitioners (n = 824) and all consultants in specialities likely to be involved in treating such patients (n = 207) in the former Northern Region were sent questionnaires asking for their views on the treatment of patients with atrial fibrillation using anticoagulants. Results: the response rate was 56% (459/824) for general practitioners and 76% (163/207) for consultants. A patient's age was of significance to many clinicians. Forty-six percent of consultants and 43% of general practitioners felt that no patient above the age of 84 years should be treated. Medico-social factors also had an important effect on whether clinicians felt patients ought to be treated with anticoagulants. ii patient's quality of life was the most important medico-social factor, with handicap and place of residence having much smaller effects. Conclusions: age and medico-social factors have an important effect on clinicians use of anticoagulants in NVAF and reluctance to treat elderly subjects is likely to explain much of the apparent under-use of this treatment.
引用
收藏
页码:285 / 289
页数:5
相关论文
共 23 条
[1]   INTEROBSERVER AGREEMENT FOR THE ASSESSMENT OF HANDICAP IN STROKE PATIENTS [J].
BAMFORD, JM ;
SANDERCOCK, PAG ;
WARLOW, CP ;
SLATTERY, J .
STROKE, 1989, 20 (06) :828-828
[2]   SURVEY OF USE OF ANTICOAGULATION IN PATIENTS WITH ATRIAL-FIBRILLATION [J].
BATH, PMW ;
PRASAD, A ;
BROWN, MM ;
MACGREGOR, GA .
BRITISH MEDICAL JOURNAL, 1993, 307 (6911) :1045-1045
[3]  
Blackshear JL, 1996, LANCET, V348, P633
[4]  
*BRIT MED ASS ETH, 1993, MED ETH TOD, P303
[5]   CANADIAN ATRIAL-FIBRILLATION ANTICOAGULATION (CAFA) STUDY [J].
CONNOLLY, SJ ;
LAUPACIS, A ;
GENT, M ;
ROBERTS, RS ;
CAIRNS, JA ;
JOYNER, C .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1991, 18 (02) :349-355
[6]   ISCHEMIC AND HEMORRHAGIC STROKE IN PATIENTS ON ORAL ANTICOAGULANTS AFTER RECONSTRUCTION FOR CHRONIC LOWER-LIMB ISCHEMIA [J].
DAWSON, I ;
VANBOCKEL, JH ;
FERRARI, MD ;
VANDERMEER, FJM ;
BRAND, R ;
TERPSTRA, JL .
STROKE, 1993, 24 (11) :1655-1663
[7]   WARFARIN IN THE PREVENTION OF STROKE ASSOCIATED WITH NONRHEUMATIC ATRIAL-FIBRILLATION [J].
EZEKOWITZ, MD ;
BRIDGERS, SL ;
JAMES, KE ;
CARLINER, NH ;
COLLING, CL ;
GORNICK, CC ;
KRAUSESTEINRAUF, H ;
KURTZKE, JF ;
NAZARIAN, SM ;
RADFORD, MJ ;
RICKLES, FR ;
SHABETAI, R ;
DEYKIN, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (20) :1406-1412
[8]   PREVALENCE, AGE DISTRIBUTION, AND GENDER OF PATIENTS WITH ATRIAL-FIBRILLATION - ANALYSIS AND IMPLICATIONS [J].
FEINBERG, WM ;
BLACKSHEAR, JL ;
LAUPACIS, A ;
KRONMAL, R ;
HART, RG .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (05) :469-473
[9]  
KISTLER JP, 1990, NEW ENGL J MED, V323, P1505
[10]  
KOUDSTAAL PJ, 1993, LANCET, V342, P1255